Annual Statements Open main menu

KEWAUNEE SCIENTIFIC CORP /DE/ - Quarter Report: 2018 October (Form 10-Q)

10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2018

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 0-5286

 

 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

  28677-2927
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer   ☐ (Do not check if a smaller reporting company)    Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

As of December 4, 2018, the registrant had outstanding 2,744,325 shares of Common Stock.

 

 

 


KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2018

 

         Page Number  
PART I. FINANCIAL INFORMATION   
Item 1.  

Financial Statements

  
 

Condensed Consolidated Statements of Operations (unaudited)
– Three and six months ended October 31, 2018 and 2017

     1  
 

Condensed Consolidated Statements of Comprehensive Income (unaudited)
– Three and six months ended October 31, 2018 and 2017

     2  
 

Condensed Consolidated Statement of Stockholders’ Equity (unaudited)
– Three and six months ended October 31, 2018

     3  
 

Condensed Consolidated Balance Sheets – October  31, 2018 (unaudited) and April 30, 2018

     4  
 

Condensed Consolidated Statements of Cash Flows (unaudited)
– Six months ended October 31, 2018 and 2017

     5  
 

Notes to Condensed Consolidated Financial Statements (unaudited)

     6  
Item 2.  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     16  
Item 3.  

Quantitative and Qualitative Disclosures About Market Risk

     19  
Item 4.  

Controls and Procedures

     19  
PART II. OTHER INFORMATION   
Item 1A.  

Risk Factors

     19  
Item 6.  

Exhibits

     19  
SIGNATURES      21  

 

i


Part 1. Financial Information

 

Item 1.

Financial Statements

Kewaunee Scientific Corporation

Condensed Consolidated Statements of Operations

(Unaudited)

($ and shares in thousands, except per share amounts)

 

     Three months ended
October 31
    Six months ended
October 31
 
     2018     2017     2018     2017  

Net sales

   $ 37,278     $ 41,471     $ 79,430     $ 75,352  

Costs of products sold

     29,505       33,560       64,183       60,620  
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     7,773       7,911       15,247       14,732  

Operating expenses

     5,963       5,256       11,726       10,389  
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating earnings

     1,810       2,655       3,521       4,343  

Other income

     150       177       314       345  

Interest expense, net

     (91     (89     (182     (148
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings before income taxes

     1,869       2,743       3,653       4,540  

Income tax expense

     415       978       783       1,583  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings

     1,454       1,765       2,870       2,957  

Less: net earnings attributable to the noncontrolling interest

     40       41       49       85  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings attributable to Kewaunee Scientific Corporation

   $ 1,414     $ 1,724     $ 2,821     $ 2,872  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

        

Basic

   $ 0.52     $ 0.64     $ 1.03     $ 1.06  

Diluted

   $ 0.51     $ 0.62     $ 1.01     $ 1.04  

Weighted average number of common shares outstanding

        

Basic

     2,743       2,717       2,740       2,715  

Diluted

     2,800       2,776       2,802       2,766  

See accompanying notes to condensed consolidated financial statements.

 

1


Kewaunee Scientific Corporation

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

($ in thousands)

 

     Three months ended
October 31
    Six months ended
October 31
 
     2018     2017     2018     2017  

Net earnings

   $ 1,454     $ 1,765     $ 2,870     $ 2,957  
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), net of tax:

        

Foreign currency translation adjustments

     (725     (229     (1,113     (154

Change in fair value of cash flow hedge

     1       10       5       18  
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

     (724     (219     (1,108     (136
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income, net of tax

     730       1,546       1,762       2,821  

Less: comprehensive income attributable to the noncontrolling interest

     40       41       49       85  
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to Kewaunee Scientific Corporation

   $ 690     $ 1,505     $ 1,713     $ 2,736  
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

2


Kewaunee Scientific Corporation

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

($ in thousands, except share and per share amounts)

 

     Six Months Ended October 31, 2018  
     Common
Stock
     Additional
Paid-in
Capital
    Treasury
Stock
    Retained
Earnings
    Accumulated
Other
Comprehensive
Income (Loss)
    Total
Stockholders’
Equity
 

Balance at April 30, 2018

   $ 6,841      $ 3,006     $ (53   $ 43,165     $ (5,900   $ 47,059  

Net earnings attributable to Kewaunee Scientific Corporation

     —          —         —         1,407       —         1,407  

Other comprehensive income (loss)

     —          —         —         —         (384     (384

Cash dividends paid, $0.17 per share

     —          —         —         (465     —         (465

Stock options exercised, 9,250 shares

     13        (13     —         —         —         —    

Stock based compensation

     7      99       —         —         —         106  

Cumulative adjustment for ASC 606, net of tax

     —          —         —         217     —         217  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at July 31, 2018

     6,861        3,092       (53     44,324       (6,284     47,940  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings attributable to Kewaunee Scientific Corporation

     —          —         —         1,414       —         1,414  

Other comprehensive income (loss)

     —          —         —         —         (724     (724

Cash dividends paid, $0.19 per share

     —          —         —         (521     —         (521

Stock options exercised, 5,800 shares

     8        (8     —         —         —         —    

Stock based compensation

     —          140       —         —         —         140  

Cumulative adjustment for accounting change, net of tax

     —          —         —         671     —         671
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at October 31, 2018

   $ 6,869      $ 3,224     $ (53   $ 45,888     $ (7,008   $ 48,920  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     Six Months Ended October 31, 2017  
     Common
Stock
     Additional
Paid-in
Capital
    Treasury
Stock
    Retained
Earnings
    Accumulated
Other
Comprehensive
Income (Loss)
    Total
Stockholders’
Equity
 

Balance at April 30, 2017

   $ 6,789      $ 2,695     $ (53   $ 39,771     $ (6,319   $ 42,883  

Net earnings attributable to Kewaunee Scientific Corporation

     —          —         —         1,148       —         1,148  

Other comprehensive income (loss)

     —          —         —         —         83       83  

Cash dividends paid, $0.15 per share

     —          —         —         (406     —         (406

Stock options exercised, 500 shares

     1        8       —         —         —         9  

Stock based compensation

     —          52       —         —         —         52  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at July 31, 2017

     6,790        2,755       (53     40,513       (6,236     43,769  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings attributable to Kewaunee Scientific Corporation

     —          —         —         1,724       —         1,724  

Other comprehensive income (loss)

     —          —         —         —         (219     (219

Cash dividends paid, $0.17 per share

     —          —         —         (462     —         (462

Stock options exercised, 15,241 shares

     15        (16     —         —         —         (1

Stock based compensation

     4      122       —         —         —         126  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at October 31, 2017

   $ 6,809      $ 2,861     $ (53   $ 41,775     $ (6,455   $ 44,937  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

3


Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

($ and shares in thousands, except per share amounts)

 

     October 31,
2018
    April 30,
2018
 
     (Unaudited)        

Assets

    

Current Assets:

    

Cash and cash equivalents

   $ 9,477     $ 9,716  

Restricted cash

     679       1,242  

Receivables, less allowance; $372; $384, on each respective date

     29,785       32,660  

Inventories

     17,097       17,662  

Prepaid expenses and other current assets

     3,251       2,224  
  

 

 

   

 

 

 

Total Current Assets

     60,289       63,504  

Property, plant and equipment, at cost

     56,120       54,648  

Accumulated depreciation

     (41,252     (39,987
  

 

 

   

 

 

 

Net Property, Plant and Equipment

     14,868       14,661  

Deferred income taxes

     1,888       2,031  

Other

     3,551       4,162  
  

 

 

   

 

 

 

Total Other Assets

     5,439       6,193  
  

 

 

   

 

 

 

Total Assets

   $ 80,596     $ 84,358  
  

 

 

   

 

 

 

Liabilities and Stockholders’ Equity

    

Current Liabilities:

    

Short-term borrowings and interest rate swaps

   $ 4,658     $ 3,885  

Current portion of long-term debt and lease obligations

     1,184       1,167  

Accounts payable

     10,726       14,754  

Employee compensation and amounts withheld

     3,162       3,810  

Deferred revenue

     1,563       1,884  

Other accrued expenses

     2,743       2,062  
  

 

 

   

 

 

 

Total Current Liabilities

     24,036       27,562  

Long-term debt

     822       1,264  

Accrued pension and deferred compensation costs

     6,016       7,465  

Income taxes payable

     339       546  
  

 

 

   

 

 

 

Total Liabilities

     31,213       36,837  

Commitments and Contingencies

    

Stockholders’ Equity:

    

Common Stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,747 shares; 2,736 shares; – Outstanding – 2,744 shares; 2,733 shares, on each respective date

     6,869       6,841  

Additional paid-in-capital

     3,224       3,006  

Retained earnings

     45,888       43,165  

Accumulated other comprehensive loss

     (7,008     (5,900

Common stock in treasury, at cost, 3 shares, on each date

     (53     (53
  

 

 

   

 

 

 

Total Kewaunee Scientific Corporation Stockholders’ Equity

     48,920       47,059  

Noncontrolling interest

     463       462  
  

 

 

   

 

 

 

Total Stockholders’ Equity

     49,383       47,521  
  

 

 

   

 

 

 

Total Liabilities and Stockholders’ Equity

   $ 80,596     $ 84,358  
  

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

4


Kewaunee Scientific Corporation

Condensed Consolidated Statements of Cash Flows

(Unaudited)

($ in thousands)

 

     Six months ended
October 31
 
     2018     2017  

Cash flows from operating activities:

    

Net earnings

   $ 2,870     $ 2,957  

Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:

    

Depreciation

     1,263       1,403  

Bad debt provision

     20       45  

Share-based compensation expense

     275       178  

Provision for deferred income taxes

     143       50  

Change in assets and liabilities:

    

Decrease (increase) in receivables

     2,855       (3,401

Decrease (increase) in inventories

     565       (1,504

(Decrease) increase in accounts payable and other accrued expenses

     (4,202     3,514  

(Decrease) in deferred revenue

     (321     (4,300

Other, net

     (1,167     (1,055
  

 

 

   

 

 

 

Net cash provided by (used in) by operating activities

     2,301       (2,113

Cash flows from investing activities:

    

Capital expenditures

     (1,311     (1,437
  

 

 

   

 

 

 

Net cash used in investing activities

     (1,311     (1,437

Cash flows from financing activities:

    

Dividends paid

     (986     (868

Dividends paid to holders of noncontrolling interest in subsidiaries

     —         (74

Proceeds from short-term borrowings

     34,135       28,476  

Repayments on short-term borrowings

     (33,362     (24,356

Payments on long-term debt and lease obligations

     (583     (334

Net proceeds from exercise of stock options

     (29     8  
  

 

 

   

 

 

 

Net cash (used in) provided by financing activities

     (825     2,852  

Effect of exchange rate changes on cash and cash equivalents

     (967     (59
  

 

 

   

 

 

 

Decrease in cash, cash equivalents and restricted cash

     (802     (757

Cash, cash equivalents and restricted cash, beginning of period

     10,958       13,941  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash, end of period

   $ 10,156     $ 13,184  
  

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

5


Kewaunee Scientific Corporation

Notes to Condensed Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim condensed consolidated financial statements of Kewaunee Scientific Corporation (the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2018 Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The condensed consolidated balance sheet as of April 30, 2018 included in this interim period filing has been derived from the audited financial statements at that date, but does not include all of the information and related notes required by generally accepted accounting principles (GAAP) for complete financial statements.

The preparation of the interim condensed consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

Adjusted Financial Information for Change in Accounting Principle

During the second quarter of 2019, the Company changed its method of accounting for its Domestic segment’s inventory from the last-in, first-out (LIFO) method to the first-in, first out (FIFO) method. All prior periods presented have been retrospectively adjusted to apply the new method of accounting. See Note E for more information on the change in inventory accounting method.

B. Revenue Recognition

The Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company’s revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company’s revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract.

Performance Obligations

A performance obligation is a distinct good or service or bundle of goods and services that is distinct or a series of distinct goods or services that are substantially the same and have the same pattern of transfer. The Company identifies performance obligations at the inception of a contract and allocates the transaction price to individual performance obligations to reasonably reflect the Company’s performance in transferring control of the promised goods or services to the customer. The Company has elected to treat shipping and handling as a fulfillment activity instead of a separate performance obligation.

The following are the primary performance obligations identified by the Company:

Laboratory Furniture

The Company principally generates revenue from the manufacture of custom laboratory, healthcare, and technical furniture and infrastructure products (herein referred to as “laboratory furniture”). The Company’s products include steel, wood, and laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Customers can benefit from each piece of laboratory furniture on its own or with resources readily available in the market place such as separately purchased installation services. Each piece of laboratory furniture does not significantly modify or customize other laboratory furniture, and the pieces of laboratory furniture are not highly interdependent or interrelated with each other. The Company can, and frequently does, break pieces of contracts into separate “runs” to meet manufacturing and construction schedules. As such, each piece of laboratory furniture is considered a separate and distinct performance obligation. The majority of the Company’s products are customized to meet the specific architectural design and performance requirements of laboratory planners and end users. The finished laboratory furniture has no alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. As such, revenue from the sales of customized laboratory furniture is recognized over time once the customization process has begun, using the units-of-production output method to measure progress towards completion. There is not a material amount of work-in-process for which the customization process has begun at the end of a reporting period. The Company believes this output method most reasonably reflects the Company’s performance because it directly measures the value of the goods transferred to the customer. For standardized products sold by the Company, revenue is recognized when control transfers, which is typically freight on board (“FOB”) shipping point.

 

6


Warranties

All orders contain a standard warranty that warrants that the product is free from defects in workmanship and materials under normal use and conditions for a limited period of time. Due to the nature and quality of the Company’s products, any warranty issues have historically been determined in a relatively short period after the sale, have been infrequent in nature, and have been immaterial to the Company’s financial position and results of operations. The Company’s standard warranties are not considered a separate and distinct performance obligation as the Company does not provide a service to customers beyond assurance that the covered product is free of initial defects. Costs of providing these short term assurance warranties are immaterial and, accordingly, are expensed as incurred. An extended separately priced warranty is available that can last up to five years. Separately priced extended warranties are considered separate performance obligations as they are a separately priced option available for purchase and they involve providing a service in addition to assurance that the product is free of defects.

Installation Services

The Company sometimes performs installation services for customers. The scope of installation services primarily relates to setting up the laboratory furniture, ensuring the proper functioning of the laboratory furniture. In certain markets, the Company may provide a broader range of installation services involving the design and installation of the laboratory’s mechanical services. Installation services can be, and often are, performed by third parties and thus may be distinct from the Company’s products. Installation services create or enhance assets that the customer controls as the installation services are provided and, as such, revenue from installation services is recognized over time as the installation services are performed using the cost input method, because there is a direct relationship between the Company’s inputs and the transfer of control of installation services to the customer.

Custodial Services

It is common in the laboratory and healthcare furniture industries for customers to request delivery at specific future dates, as products are often to be installed in buildings yet to be constructed. Frequently, customers will request the manufacture of these products prior to the customer’s ability or readiness to receive the product due to various reasons such as changes to or delays in the construction of the building. As such, from time to time our customers require us to provide custodial services for their laboratory furniture. Custodial services are frequently provided by third parties and do not significantly alter the other goods or services covered by the contract and as such are considered a separate and distinct performance obligation. Custodial services are simultaneously received and consumed by the customer and as such revenue from custodial services is recognized over time using a straight-line time-based measure of progress towards completion, because the Company’s services are provided evenly throughout the performance period.

Payment Terms and Transaction Prices

Our contracts with customers are fixed-priced and do not contain variable consideration or a general right of return or refund. Our contracts with customers contain terms typical for our industry, including withholding a portion of the transaction price until after the goods or services have been transferred to the customer (i.e. “retainage”). The Company does not recognize this as a significant financing component because the primary purpose of retainage is to provide the customer with assurance that the Company will perform its obligations under the contract, rather than to provide financing to the customer.

Allocation of Transaction Price

Our contracts with customers may contain multiple goods and services, such as differing types of laboratory furniture and installation services. For these arrangements, each good or service is evaluated to determine whether it represents a distinct performance obligation. The total transaction price is then allocated to the distinct performance obligations based on their relative standalone selling price at the inception of the arrangement. If available, the Company utilizes observable prices for goods or services sold separately to similar customers in similar circumstances to determine its relative standalone selling price. Otherwise, list prices are used if they are determined to be representative of standalone selling prices. If neither of these methods are available at contract inception, such as when we do not sell the product or service separately, judgment may be required and we determine the standalone selling price using one, or a combination of, the adjusted market assessment or expected cost-plus margin approaches.

Practical Expedients Used

ASC 606 permits the use of practical expedients under certain conditions. We have elected the following practical expedients allowed under ASC 606:

 

   

Under the modified retrospective approach the Company elected to reassess revenue recognition under ASC 606 for only those contracts open as of the adoption date.

 

7


   

The portfolio approach was applied in evaluating the accounting for the cost of obtaining a contract.

 

   

Payment terms with our customers which are one year or less are not considered a significant financing component.

 

   

The Company excludes from revenues taxes it collects from customers that are assessed by a government authority. This is primarily relevant to domestic sales but also includes taxes on some international sales which are also excluded from the transaction price.

 

   

Our incremental cost to obtain a contract is limited to sales commissions. We apply the practical expedient to expense commissions as incurred for contracts having a duration of one year or less. Sales commissions related to contracts with a duration of greater than one year are immaterial to the company’s consolidated financial position and results of operations and are also expensed as incurred.

Disaggregated Revenue

A summary of net sales transferred to customers at a point in time and over time for the three and six months ended October 31, 2018 is as follows (in thousands):

 

     Three Months Ended October 31, 2018  
     Domestic      International      Total  

Over Time

   $ 28,311      $ 6,656      $ 34,967  

Point in Time

     2,311        —          2,311  
  

 

 

    

 

 

    

 

 

 
   $ 30,622      $ 6,656      $ 37,278  
  

 

 

    

 

 

    

 

 

 

 

     Six Months Ended October 31, 2018  
     Domestic      International      Total  

Over Time

   $ 62,559      $ 12,738      $ 75,297  

Point in Time

     4,133        —          4,133  
  

 

 

    

 

 

    

 

 

 
   $ 66,692      $ 12,738      $ 79,430  
  

 

 

    

 

 

    

 

 

 

Contract Balances

The closing and opening balances of contract assets and liabilities arising from contracts with customers were $1,563,000 at October 31, 2018 and $1,884,000 at April 30, 2018. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue on the condensed consolidated balance sheets. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms. Accounts receivable are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract.

During the three and six months ended October 31, 2018, changes in contract assets and liabilities were not materially impacted by any other factors. Approximately 100% of the contract liability balance at April 30, 2018 is expected to be recognized as revenue during fiscal year 2019 and 35% and 81% of this amount was recognized during the three and six months ended October 31, 2018, respectively.

ASC 606 adoption impact

Under ASC 606, sales consisting of customized products sold to customers for which revenue was previously recognized at a point in time now meet the criteria of a performance obligation satisfied over time. These contracts consist of customized laboratory furniture engineered or tailored to meet the customer’s requirements. In the event the customer cancels the contract, the Company will have no alternative use for and cannot economically repurpose the laboratory furniture, and the Company has the right to payment for performance completed to date. This change results in accelerated recognition of revenue and increases the balance of contract assets compared to the previous revenue recognition standard.

The Company adopted ASC 606 on May 1, 2018 using the modified retrospective approach and elected to reassess revenue recognition under ASC 606 for only those contracts open as of the adoption date, which resulted in a cumulative effect adjustment to increase Retained Earnings, net of tax, of $217,000. Comparative information for prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods presented. The Company elected to reflect the aggregate effect of all contract modifications that occurred before the beginning of the earliest period presented in determining the transaction price, identifying the satisfied and unsatisfied performance obligations and allocating the transaction price to the satisfied and unsatisfied performance obligations for the modified contract at transition. The effects of these elections were immaterial.

 

8


The following table summarizes the impact of adopting ASC 606 on the condensed consolidated statements of operations:

 

     Three Months Ended October 31, 2018  
     ($ in thousands, except per share amounts)  
     As Reported      Adjustments      Balance Without
Adoption of
ASC 606
 

Net sales

   $ 37,278      $ 1,117      $ 38,395  

Costs of products sold

     29,505        1,035        30,540  
  

 

 

    

 

 

    

 

 

 

Gross profit

     7,773        82        7,855  

Operating expenses

     5,963        3        5,966  
  

 

 

    

 

 

    

 

 

 

Operating earnings

     1,810        79        1,889  

Other income

     150        —          150  

Interest expense

     (91      —          (91
  

 

 

    

 

 

    

 

 

 

Earnings before income taxes

     1,869        79        1,948  

Income tax expense

     415        25        440  
  

 

 

    

 

 

    

 

 

 

Net earnings

     1,454        54        1,508  

Net earnings attributable to the noncontrolling interest

     40        —          40  
  

 

 

    

 

 

    

 

 

 

Net earnings attributable to Kewaunee Scientific Corporation

     1,414        54        1,468  
  

 

 

    

 

 

    

 

 

 

Basic Earnings Per Share

   $ 0.52      $ 0.02      $ 0.54  

Diluted Earnings Per Share

   $ 0.51      $ 0.02      $ 0.53  

 

     Six Months Ended October 31, 2018  
     ($ in thousands, except per share amounts)  
     As Reported      Adjustments      Balance Without
Adoption of
ASC 606
 

Net sales

   $ 79,430      $ (52    $ 79,378  

Costs of products sold

     64,183        350        64,533  
  

 

 

    

 

 

    

 

 

 

Gross profit

     15,247        (402      14,845  

Operating expenses

     11,726        5        11,731  
  

 

 

    

 

 

    

 

 

 

Operating earnings

     3,521        (407      3,114  

Other income

     314        —          314  

Interest expense

     (182      —          (182
  

 

 

    

 

 

    

 

 

 

Earnings before income taxes

     3,653        (407      3,246  

Income tax expense

     783        (92      691  
  

 

 

    

 

 

    

 

 

 

Net earnings

     2,870        (315      2,555  

Net earnings attributable to the noncontrolling interest

     49        —          49  
  

 

 

    

 

 

    

 

 

 

Net earnings attributable to Kewaunee Scientific Corporation

     2,821        (315      2,506  
  

 

 

    

 

 

    

 

 

 

Basic Earnings Per Share

   $ 1.03      $ (0.11    $ 0.92  

Diluted Earnings Per Share

   $ 1.01      $ (0.11    $ 0.90  

 

9


The following table summarizes the impact of adopting ASC 606 on the Company’s condensed consolidated balance sheet:

 

     October 31, 2018  
     ($ in thousands)  
     As Reported      Adjustments      Balance Without
Adoption of
ASC 606
 

Assets

        

Cash and cash equivalents

   $ 9,477         $ 9,477  

Restricted cash

     679           679  

Receivables, less allowances

     29,785        (2,297      27,488  

Inventories

     17,097        1,587        18,684  

Prepaid expenses and other assets

     3,251           3,251  
  

 

 

    

 

 

    

 

 

 

Total Current Assets

     60,289        (710      59,579  

Net property, plant and equipment

     14,868           14,868  

Other assets

     5,439           5,439  
  

 

 

    

 

 

    

 

 

 

Total Assets

   $ 80,596      $ (710    $ 79,886  
  

 

 

    

 

 

    

 

 

 

Liabilities and Stockholders’ Equity

        

Short-term borrowings and interest rate swaps

   $ 4,658      $ —      $ 4,658  

Current portion of long-term debt and lease obligations

     1,184        —          1,184  

Accounts payable

     10,726        (10      10,716  

Other current liabilities

     7,468        (168      7,300  
  

 

 

    

 

 

    

 

 

 

Total Current Liabilities

     24,036        (178      23,858  

Other non-current liabilities

     7,177        —          7,177  
  

 

 

    

 

 

    

 

 

 

Total Liabilities

     31,213        (178      31,035  

Noncontrolling interest

     463        —          463  

Total Kewaunee Scientific Corporation Stockholders’ Equity

     48,920        (532      48,388  
  

 

 

    

 

 

    

 

 

 

Total Stockholders’ Equity

     49,383        (532      48,851  
  

 

 

    

 

 

    

 

 

 

Total Liabilities and Stockholders’ Equity

   $ 80,596      $ (710    $ 79,886  
  

 

 

    

 

 

    

 

 

 

C. Derivative Financial Instruments

The Company records derivatives on the condensed consolidated balance sheets at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Company’s business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company does not enter into derivative instruments for speculative purposes. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $3,450,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.875% for the period beginning May 1, 2013 and ending August 1, 2017. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $2,600,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.37% for the period beginning August 1, 2017 and ending May 1, 2020. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $1,218,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 3.07% for the period beginning November 3, 2014 and ending May 1, 2020. The Company entered into these interest rate swap arrangements to mitigate future interest rate risk associated with its long-term debt and has designated these as cash flow hedges.

D. Earnings Per Share

Basic earnings per share is based on the weighted average number of common shares outstanding during the three and six month periods. Diluted earnings per share reflects the assumed exercise and conversion of restricted stock units and outstanding stock options under the Company’s Omnibus Incentive Plan, except when such awards have an anti-dilutive effect. There were no antidilutive awards outstanding at October 31, 2018 and October 31, 2017.

E. Inventories

Effective August 1, 2018, the Company elected to change its method of inventory accounting to the first in, first out (“FIFO”) method from the last in, first out (“LIFO”) link-chain dollar-value method for its Domestic segment inventories. The Company has previously

 

10


incorrectly disclosed that it used the double-extension technique to calculate its LIFO reserve. The Company believes that the FIFO method is preferable as it results in increased uniformity across the Company’s operations with respect to the inventory valuation method, as the Company’s International subsidiaries use the FIFO method. The Company also believes that the change to FIFO will improve financial reporting by better reflecting the current value of inventory on the condensed consolidated balance sheets, by more closely aligning the flow of physical inventory with the accounting for the inventory, providing better matching of revenues and expenses. The Company applied this change in method of inventory accounting by retrospectively adjusting all prior period financial statements and footnote information presented herein as necessary.

There was no impact upon the Company’s condensed consolidated statements of operations for the three-month and six-month periods ended October 31, 2017 as there was no adjustment to the LIFO reserve amount during those periods. Consequently, there was no change in the Company’s condensed consolidated statement of cash flows for the six-month period ending October 31, 2017. Inventories consisted of the following (in thousands):

 

     October 31,
2018
     As Adjusted
April 30, 2018
 

Finished products

   $ 3,807      $ 4,987  

Work in process

     1,375        2,393  

Raw materials

     11,915        11,169  
  

 

 

    

 

 

 
   $ 17,097      $ 18,549  
  

 

 

    

 

 

 

The Company’s International subsidiaries’ inventories were $1,258,000 at October 31, 2018 and $1,908,000, at April 30, 2018, measured using the first-in, first-out (“FIFO”) method at the lower of cost and net realizable value and are included in the above tables. Certain amounts in the Company’s condensed consolidated balance sheet as of April 30, 2018 was adjusted as follows (in thousands):

 

     April 30, 2018  
     As Originally
Reported
     Adjustments      As Adjusted  

Inventories

   $ 17,662      $ 887      $ 18,549  

Total Current Assets

     63,504        887        64,391  

Deferred income taxes

     2,031        (162      1,869  

Total Assets

     84,358        725        85,083  

Other accrued expenses

     2,062        54        2,116  

Total Current Liabilities

     27,562        54        27,616  

Total Liabilities

     36,837        54        36,891  

Retained earnings

     43,165        671        43,836  

Total Kewaunee Scientific Corporation Stockholders’ Equity

     47,059        671        47,730  

Total Stockholders’ Equity

     47,521        671        48,192  

Total Liabilities and Stockholders’ Equity

   $ 84,358      $ 725      $ 85,083  

 

11


Certain amounts in the Company’s condensed consolidated statement of operations for the three and six months ended October 31, 2018 under the former LIFO method would have been as follows (in thousands, except per share amounts):

 

     Three months ended October 31, 2018  
     As reported under
FIFO
     Adjustments      As computed under
LIFO
 

Cost of products sold

   $ 29,505      $ 100      $ 29,605  

Income tax (benefit)

     415        (24      391  

Net earnings

     1,454        (76      1,378  

Net earnings attributable to Kewaunee Scientific Corporation

   $ 1,414      $ (76    $ 1,338  

Net earnings attributable to Kewaunee Scientific Corporation shareholders

        

Basic

   $ 0.52      $ (0.03    $ 0.49  

Diluted

   $ 0.51      $ (0.03    $ 0.48  

 

     Six months ended October 31, 2018  
     As reported under
FIFO
     Adjustments      As computed under
LIFO
 

Cost of products sold

   $ 64,183      $ 200      $ 64,383  

Income tax (benefit)

     783        (49      734  

Net earnings

     2,870        (151      2,719  

Net earnings attributable to Kewaunee Scientific Corporation

   $ 2,821      $ (151    $ 2,670  

Net earnings attributable to Kewaunee Scientific Corporation shareholders

        

Basic

   $ 1.03      $ (0.05    $ 0.98  

Diluted

   $ 1.01      $ (0.05    $ 0.96  

Certain amounts in the Company’s condensed consolidated statement of cash flows as of October 31, 2018 would have been as follows under the former LIFO method (in thousands):

 

     Six months ended October 31, 2018  
     As reported under
FIFO
     Adjustments      As computed under
LIFO
 

Net earnings

   $ 2,870      $ (151    $ 2,719  

Decrease (increase) in inventories

     565        200        765  

Decrease (increase) in accounts payable and other accrued expenses

     (4,202      (49      (4,251

Net cash provided by (used in) operating activities

   $ 2,301      $ —        $ 2,301  

Certain amounts in the Company’s condensed consolidated balance sheet as of October 31, 2018 would have been as follows under the former LIFO method (in thousands):

 

     October 31, 2018  
     As reported under
FIFO
     Adjustment      As computed under
LIFO
 

Inventories

   $ 17,097      $ (1,087    $ 16,010  

Total Current Assets

     60,289        (1,087      59,202  

Deferred income taxes

     1,888        162        2,050  

Total Assets

     80,596        (925      79,671  

Other accrued expenses

     2,743        (103      2,640  

Total Current Liabilities

     24,036        (103      23,933  

Total Liabilities

     31,213        (103      31,110  

Retained earnings

   $ 45,888      $ (822    $ 45,066  

Total Kewaunee Scientific Corporation Stockholders’ Equity

     48,920        (822      48,098  

Total Stockholders’ Equity

     49,383        (822      48,561  

Total Liabilities and Stockholders’ Equity

   $ 80,596      $ (925    $ 79,671  

 

12


F. Segment Information

The Company’s operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company’s foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments.

The following table provides financial information by business segments for the three and six months ended October 31, 2018 and 2017 (in thousands):

 

     Domestic
Operations
     International
Operations
     Corporate /
Eliminations
     Total  

Three months ended October 31, 2018

           

Revenues from external customers

   $ 30,622      $ 6,656      $ —      $ 37,278  

Intersegment revenues

     416        1,108        (1,524      —    

Earnings (loss) before income taxes

     2,946        705        (1,782      1,869  

Three months ended October 31, 2017

           

Revenues from external customers

   $ 28,540      $ 12,931      $ —      $ 41,471  

Intersegment revenues

     5,068        1,062        (6,130      —    

Earnings (loss) before income taxes

     2,945        1,286        (1,488      2,743  

 

     Domestic
Operations
     International
Operations
     Corporate/
Eliminations
     Total  

Six months ended October 31, 2018

           

Revenues from external customers

   $ 66,692      $ 12,738      $ —      $ 79,430  

Intersegment revenues

     878        1,834        (2,712      —    

Earnings (loss) before income taxes

     5,945        1,154        (3,446      3,653  

Six months ended October 31, 2017

           

Revenues from external customers

   $ 50,686      $ 24,666      $ —      $ 75,352  

Intersegment revenues

     9,153        1,930        (11,083      —    

Earnings (loss) before income taxes

     4,761        2,656        (2,877      4,540  

G. Defined Benefit Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. Company contributions of $1,000,000 were paid to the plans during the six months ended October 31, 2018, and the Company does not expect any contributions to be paid to the plans during the remainder of the fiscal year. Contributions of $600,000 were paid to the plans during the six months ended October 31, 2017. The Company assumed an expected long-term rate of return of 7.75% for the period ended October 31, 2018 as compared to 7.75% for the period ended October 31, 2017. Pension expense consisted of the following (in thousands):

 

     Three months ended
October 31, 2018
     Three months ended
October 31, 2017
 

Service cost

   $ -0-      $ -0-  

Interest cost

     215        219  

Expected return on plan assets

     (362      (317

Recognition of net loss

     221        283  
  

 

 

    

 

 

 

Net periodic pension expense

   $ 74      $ 185  
  

 

 

    

 

 

 

 

13


     Six months ended
October 31, 2018
     Six months ended
October 31, 2017
 

Service cost

   $ -0-      $ -0-  

Interest cost

     430        438  

Expected return on plan assets

     (724      (656

Recognition of net loss

     442        566  
  

 

 

    

 

 

 

Net periodic pension expense

   $ 148      $ 348  
  

 

 

    

 

 

 

H. Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of cash and equivalents, mutual funds, cash surrender value of life insurance policies, term loans and short-term borrowings. The carrying value of these assets and liabilities approximate their fair value. The following tables summarize the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2018 and April 30, 2018 (in thousands):

 

     October 31, 2018  

Financial Assets

   Level 1      Level 2      Total  

Trading securities held in non-qualified compensation plans (1)

   $ 3,443      $ —      $ 3,443  

Interest rate swap derivatives

     —          2      2  

Cash surrender value of life insurance policies (1)

     —          65        65  
  

 

 

    

 

 

    

 

 

 

Total

   $ 3,443      $ 67      $ 3,510  
  

 

 

    

 

 

    

 

 

 

Financial Liabilities

        

Non-qualified compensation plans (2)

   $ —      $ 3,864      $ 3,864  
  

 

 

    

 

 

    

 

 

 
     April 30, 2018  

Financial Assets

   Level 1      Level 2      Total  

Trading securities held in non-qualified compensation plans (1)

   $ 4,050      $ —      $ 4,050  

Cash surrender value of life insurance policies (1)

     —          65        65  
  

 

 

    

 

 

    

 

 

 

Total

   $ 4,050      $ 65      $ 4,115  
  

 

 

    

 

 

    

 

 

 

Financial Liabilities

        

Non-qualified compensation plans (2)

   $ —      $ 4,462      $ 4,462  

Interest rate swap derivatives

     —          5        5  
  

 

 

    

 

 

    

 

 

 

Total

   $ —      $ 4,467      $ 4,467  
  

 

 

    

 

 

    

 

 

 

 

(1)

The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value.

(2)

Plan liabilities are equal to the individual participants’ account balances and other earned retirement benefits.

I. Stock Options and Share-based Compensation

The Company adopted ASU 2016-9, “Stock Compensation – Improvements to Employee Share-Based Payment Accounting” prospectively effective May 1, 2017. Prior periods were not retrospectively adjusted. The Company elected prospectively to account for forfeitures as they occur rather than apply an estimated rate to share-based compensation expense. Compensation costs related to stock options and other stock awards granted by the Company are charged against operating expenses during their vesting period, under ASC 718, “Compensation – Stock Compensation.”

 

14


The Company granted 17,769 restricted stock units (“RSUs”) under the 2017 Omnibus Incentive Plan in June 2018. The RSUs include both a service and a performance component, vesting over a three year period. The recognized expense is based upon the vesting period for service criteria and estimated attainment of the performance criteria at the end of the three year period based on the ratio of cumulative days incurred, to total days over the three year period. The Company recorded share-based compensation expense during the three and six months ended October 31, 2018 of $46,000 and $61,000, respectively, for this issuance with the remaining estimated share-based compensation expense of $451,000 to be recorded over the remaining three year period.

J. Income Taxes

On December 22, 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was signed into law. The 2017 Tax Act includes a broad range of tax reform provisions affecting businesses, including lower corporate tax rates, changes in business deductions, and international tax provisions. In response to the 2017 Tax Act, the U.S. Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations where a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. SAB 118 provides that the measurement period is complete when a company’s accounting is complete and that the measurement period shall not extend beyond one year from the enactment date. SAB 118 provides guidance for registrants under three scenarios: (i) measurement of certain income tax effects is complete, (ii) measurement of certain income tax effects can be reasonably estimated, and (iii) measurement of certain income tax effects cannot be reasonably estimated.

The Company has analyzed the income tax effects of the 2017 Tax Act and determined that measurement of the income tax effects can be reasonably estimated, and, as such, provisional amounts have been recorded. The Company believes that all provisional amounts reflected in its financial statements are based on the best estimates that can be made at this time. The Company will continue to analyze all impacts of the 2017 Tax Act and will update provisional amounts as required.

The 2017 Tax Act also includes a one-time transition tax on accumulated unrepatriated foreign earnings. The Company has not yet completed the calculation of the related income tax pools for all of its foreign subsidiaries. The Company anticipates additional future impacts at a U.S., state and local tax level related to the 2017 Tax Act as statutory and interpretive guidance continues to become available from applicable tax authorities needed to record the complete tax expense. The Company recorded a reduction of tax expense of $2,000 during the three months and six months ended October 31, 2018 in regard to the provisional amounts recorded at April 30, 2018.

In January 2018, the FASB released guidance on the accounting for tax on the global intangible low-taxed income (“GILTI”) provisions of the Tax Act. The GILTI provisions impose a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The guidance indicates that companies must make a policy decision to either record deferred taxes related to GILTI inclusions or treat any taxes on GILTI inclusions as period costs. The Company is continuing to evaluate these options and will make its decision regarding the accounting policy election within the measurement period as provided under SAB 118. The Company has included estimated tax expense related to GILTI for current year operations in the forecasted effective tax rate.

K. Reclassifications

In connection with our adoption of ASU 2016-18, “Statement of Cash Flows-Restricted Cash,” the Company reclassified certain 2017 amounts in the condensed consolidated statements of cash flows to include restricted cash when reconciling the beginning-of-period and end-of-period cash amounts shown on the statement of cash flows to conform to the current period presentation. To comply with the SEC’s final rule on Disclosure Simplification, the Company’s presentation of the prior period’s condensed consolidated statement of stockholders’ equity has been reclassed to conform to the current period format.

L. New Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). This update outlined a new comprehensive revenue recognition model that supersedes most current revenue recognition guidance and required companies to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflected the consideration to which the entity expected to be entitled in exchange for those goods or services. The Company adopted this standard effective May 1, 2018. See Note B for a discussion of the impact of the adoption of this standard.

In August 2016, the FASB issued ASU 2016-15, “Cash Flow Classification of Certain Cash Receipts and Cash Payments,” which clarifies guidance on classification of certain transactions in the statement of cash flows, including classification of debt prepayments, debt extinguishment costs and contingent consideration payments after a business combination. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.

 

15


In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows – Restricted Cash,” which requires that the statement of cash flows reconcile the change during the period in total cash, cash equivalents and restricted cash. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.

In March 2017, the FASB issued ASU 2017-07, “Compensation – Retirement Benefits – Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost,” which requires that the service cost component of net periodic pension cost is presented in the same line as other compensation costs arising from services rendered by the respective employees during the year. The other components of net periodic pension cost are required to be presented in the income statement separately from the service cost component and outside of earnings from operations. This guidance allows for the service cost component to be eligible for capitalization when applicable. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.

In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation – Scope of Modification Accounting.” This guidance was issued in an effort to reduce diversity in practice as it relates to applying modification accounting for changes to the terms and conditions of share-based payment awards. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption permitted. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders’ equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule is effective on November 5, 2018. The Company adopted this final rule effective for the second quarter of fiscal 2019. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2018 Annual Report to Stockholders contains management’s discussion and analysis of the Company’s financial condition and results of operations as of and for the year ended April 30, 2018. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2018. The analysis of results of operations compares the three and six months ended October 31, 2018 with the comparable periods of the prior year.

Critical Accounting Policies

Inventories

The Company’s inventories are valued at the lower of cost or net realizable value. Prior to August 1, 2018, the Company’s Domestic segment’s inventories were valued under the last-in, first-out (“LIFO”) valuation method. On August 1, 2018, the Company changed its method of valuing inventory for the Domestic segment from LIFO to first-in, first-out (“FIFO”). The Company believes that this method change to FIFO will improve financial reporting by better reflecting the current value of inventory on the consolidated balance sheet, more closely aligning the flow of physical inventory with the accounting for the inventory, and providing better matching of revenues and expenses. Inventories at our International subsidiaries are, and remain, measured on the first-in, first-out (“FIFO”) method.

Results of Operations

Sales for the quarter were $37,278,000, a 10.1% decrease from sales of $41,471,000 in the prior year second quarter. Domestic sales for the quarter were $30,622,000, up 7.3% from sales of $28,540,000 in the second quarter of last year. International sales for the quarter were $6,656,000, down 48.5% from sales of $12,931,000 in the second quarter last year. Domestic sales increased year-over-year due to strength in the Company’s dealer and distribution channels as organizations continue to invest in laboratory projects that require Kewaunee’s world class products. As highlighted in the Company’s first quarter press release, Kewaunee’s International segment delivered a very large order in the Middle East during the prior year, which continues to affect the comparison of operating performance of the International segment in the current fiscal year. The significant year-over-year decline in the exchange rate of the Indian rupee versus the US dollar negatively impacted Kewaunee’s International segment performance as well.

 

16


Sales for the six months ended October 31, 2018 were $79,430,000, an increase of 5.4% from sales of $75,352,000 in the comparable period of the prior year. Domestic sales were $66,692,000, up from $50,686,000 in the comparable period of the prior year. International sales were $12,738,000, down from sales of $24,666,000 in the comparable period of the prior year due to the impact of a large order being delivered to a customer in the Middle East in the prior year.

The Company’s order backlog was $101 million at October 31, 2018, as compared to $118 million at October 31, 2017, and $102 million at July 31, 2018. The prior year’s order backlog contained a single large Middle East order that was delivered in fiscal year 2018, the absence of which primarily accounted for the decline in the order backlog in the current period.

The gross profit margin for the three months ended October 31, 2018 was 20.9% of sales as compared to 19.1% of sales in the comparable quarter of the prior year. The increase in gross profit margin percent was primarily due to continued execution of the Company’s cost reduction and productivity improvement programs, which were partially offset by a year-over-year decline in sales, as well as continued increases in raw material and freight costs.

The gross profit margin for the six months ended October 31, 2018 was 19.2% of sales, as compared to 19.6% of sales in the comparable period of the prior year. The decrease in gross profit margin percentage was primarily due to an unfavorable shift in product mix, and year-over-year decline in sales, as well as continued increases in raw material and freight costs which negatively affected margins compared to the prior period.

Operating expenses for the three months ended October 31, 2018 were $5,963,000, or 16.0% of sales, as compared to $5,256,000, or 12.7% of sales, in the comparable period of the prior year. The increase in operating expenses for the three months ended October 31, 2018 related primarily to increases in professional fees of $398,000, consulting expenses of $116,000 and International operating expenses of $295,000, partially offset by a decrease in pension expense of $111,000. The increases in professional and consulting fees were related to the Company’s preparations in anticipation of potentially moving from smaller reporting company status to accelerated filer status for SEC reporting purposes, and increased compliance costs related to implementing the provisions of the Tax Reform Act of 2017. The increase in International operating expenses related to investments made to expand the Company’s presence and capabilities in the Middle East and India.

Operating expenses for the six months ended October 31, 2018 were $11,726,000 or 14.8% of sales, as compared to $10,389,000, or 13.8% of sales, in the comparable period of the prior year. The increase in operating expenses for the six months ended October 31, 2018 related primarily to increases in professional fees of $400,000, consulting expenses of $322,000 and International operating expenses of $447,000, partially offset by a decrease in pension expense $200,000. The reasons for the increases in professional, consulting fees and International operating expenses were substantially the same as those described above with respect to the increases in the most recent quarter.

Interest expense was $91,000 and $182,000 for the three and six months ended October 31, 2018, as compared to $89,000 and $148,000 for the comparable periods of the prior year. The changes in interest expense in the current three and six month periods were primarily attributable to changes in the borrowing levels.

Income tax expense of $415,000 and $978,000 was recorded for the three months ended October 31, 2018 and 2017, respectively. The effective tax rates were 22.2% and 35.7% for the three months ended October 31, 2018 and 2017, respectively. Income tax expense of $783,000 and $1,583,000 was recorded for the six months ended October 31, 2018 and 2017, respectively. The effective tax rates were 21.4% and 34.9% for the six months ended October 31, 2018 and 2017, respectively. The decreases in the effective tax rates for the three and six month periods reflect the favorable impact of the lower federal 21% statutory rate that was effective in the current fiscal year as a result of the enactment of the Tax Cuts and Jobs Act, which was signed into law in December 2017.

Noncontrolling interests related to the Company’s subsidiary not 100% owned by the Company reduced net earnings by $40,000 and $49,000 for the three and six months ended October 31, 2018, as compared to $41,000 and $85,000 for the comparable periods of the prior year. The change in the net earnings attributable to the noncontrolling interest in the current period was due to changes in earnings of the subsidiary in the related period.

Net earnings of $1,414,000, or $0.51 per diluted share, were reported for the three months ended October 31, 2018, compared to net earnings of $1,724,000, or $0.62 per diluted share, in the prior year period. Net earnings of $2,821,000, or $1.01 per diluted share, were reported for the six months ended October 31, 2018, compared to net earnings of $2,872,000, or $1.04 per diluted share, in the prior year period.

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases. The Company believes that these sources will be sufficient to support ongoing business requirements in the current year, including capital expenditures.

 

17


The Company had working capital of $36,253,000 at October 31, 2018, compared to $35,942,000 million at April 30, 2018. The ratio of current assets to current liabilities was 2.5-to-1.0 at October 31, 2018, compared to 2.3-to-1.0 at April 30, 2018. At October 31, 2018, advances of $4.6 million were outstanding under the Company’s bank revolving credit facility, compared to advances of $3.8 million outstanding as of April 30, 2018. The Company had standby letters of credit outstanding of $5.2 million at October 31, 2018 and April 30, 2018. Amounts available under the $20 million revolving credit facility were $10.2 million and $11.0 million at October 31, 2018 and April 30, 2018, respectively. Total borrowings and interest rate swaps were $6,664,000 at October 31, 2018, compared to $6,316,000 at April 30, 2018.

The Company’s operations provided cash of $2,301,000 during the six months ended October 31, 2018. Cash was primarily provided by earnings, a decrease in receivables of $2,855,000 and a decrease in inventories of $565,000, partially offset by a decrease in accounts payable of $4,202,000 and deferred revenue of $321,000. The Company’s operations used cash of $2,113,000 during the six months ended October 31, 2017. Cash was primarily used to support an increase in managed working capital to support increased business volumes, and a decrease in deferred revenue of $4,300,000, partially offset by cash provided by earnings and an increase in accounts payable and other accrued expenses of $3,514,000.

During the six months ended October 31, 2018, the Company used net cash of $1,311,000 in investing activities, all of which was used for capital expenditures. During the six months ended October 31, 2017, net cash of $1,437,000 was used in investing activities, all of which was used for capital expenditures.

The Company’s financing activities used cash of $825,000 during the six months ended October 31, 2018, primarily for cash dividends of $986,000 paid to stockholders and payments of $583,000 on long-term debt, partially offset by an increase in net short-term borrowings of $773,000. The Company’s financing activities provided cash of $2,852,000 during the six months ended October 31, 2017, primarily from an increase in short-term borrowings of $4,120,000, partially offset by cash dividends of $868,000 paid to stockholders, cash dividends of $74,000 paid to minority interest holders and payments on long-term debt of $334,000.

Outlook

The Company’s ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors. Demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s earnings are also impacted by fluctuations in prevailing pricing for projects in the laboratory construction marketplace and increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales. Additionally, since prices are normally quoted on a firm basis in the industry, the Company bears the burden of possible increases in labor and material costs between the quotation of an order and delivery of a product. Looking forward, the Company’s third quarter is historically the most challenging quarter; however, the Company has a solid order backlog for the quarter and the remainder of the year. In addition, the Company has a strong volume of outstanding quotations globally and expects to continue to be awarded significant projects over the balance of the fiscal year. The Company continues to focus on operating cost and productivity improvements across all of its operations to offset the continued raw material cost increases. The Company does not expect the raw material cost headwinds to subside based on the current geopolitical climate.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This report contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to, competitive and general economic conditions, both domestically and internationally; changes in customer demands; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; and acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. Many important factors that could cause such a difference are described under the caption “Risk Factors” in Item 1A in the Company’s 2018 Annual Report on Form 10-K and in Quarterly Reports on Form 10-Q subsequently filed by the Company. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

18


Item 3.

Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2018.

 

Item 4.

Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of October 31, 2018. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of October 31, 2018, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

 

Item 1A.

Risk Factors

Other than as set forth in Part II, Item 1A of our Quarterly Report on Form 10-Q for the period ended July 31, 2018, there have been no material changes to the risk factors faced by the Company from those previously disclosed in our Annual Report on Form 10-K for the year ended April 30, 2018.

 

Item 6.

Exhibits

 

10.53*    Change of Control Employment Agreement dated August 21, 2018 between Kewaunee Scientific Corporation and Ryan Noble
10.54*    Change of Control Employment Agreement dated August 30, 2018 between Kewaunee Scientific Corporation and Lisa Ryan

 

19


18    Preferability Letter
31.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section  302 of the Sarbanes-Oxley Act of 2002.
31.2    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section  302 of the Sarbanes-Oxley Act of 2002.
32.1    Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section  906 of the Sarbanes-Oxley Act of 2002.
32.2    Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS    XBRL Instance Document
101.SCH    XBRL Taxonomy Extension Schema Document
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document
101.LAB    XBRL Taxonomy Extension Label Linkbase Document
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document

 

*

The referenced exhibit is a management contract or compensatory plan or arrangement.

 

20


SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

KEWAUNEE SCIENTIFIC CORPORATION

                             (Registrant)

Date: December 13, 2018     By   /s/ Thomas D. Hull III
     

Thomas D. Hull III

      (As duly authorized officer and Vice President, Finance and Chief Financial Officer)

 

21